ClinicalTrials.gg
CompletedNCT07420556Updated Aug 19, 2026

Effect of Different HPV Education Methods on Vaccination Intention in Young Women

An interventional study of Video-Based HPV Education and Face-to-Face HPV Education in Human Papillomavirus (HPV) Infection and HPV Vaccination Acceptance/Intention, sponsored by Emel GÜÇLÜ CİHAN. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Emel GÜÇLÜ CİHAN · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
18 Years to 24 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Papillomavirus Infections with a site in Turkey — 1 open to participants now, 2 under way, none of them phase 3. Papillomavirus Infections · Turkey.

Enrollment
3rd of 15
159 · median 90
Started
2025
with 2 others
No phase
15 of 19
none open now
Registered
12th of 19
by date
Lead sponsor
1 of 19
Emel GÜÇLÜ CİHAN

Among the 19 studies in Papillomavirus Infections with a site in Turkey, this one is the 3rd largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2025, is one of 15 with no phase, and was the 12th registered.

Papillomavirus Infections

581 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

1 of the 19 studies in Papillomavirus Infections with a site in Turkey is open now. Recruiting first, the newest first:

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 89 Papillomavirus Infections studies recruiting now, 40 (45%) set no upper age limit and 44 (49%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 24 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Papillomavirus Infections with a site in Turkey, or all of them as a file.
02

Study summary

Detailed Description Human papillomavirus (HPV) is one of the leading causes of cervical cancer and can be prevented by vaccination. However, HPV vaccination rates among young women are low, largely due to insufficient knowledge and misconceptions about HPV and the vaccine. Therefore, an effective educational program may improve both knowledge and vaccination intention.

The aim of this randomized controlled trial is to examine the effect of delivering HPV education through different methods (asynchronous online education delivered via a pre-recorded video and face-to-face education) on HPV knowledge level and HPV vaccination intention among women aged 18-24 years.

The study will be conducted with women aged 18-24 years registered at Family Health Centers in the Afşin district of Kahramanmaraş, Türkiye. Eligible participants will be randomly assigned into three groups: the video-based education group, the face-to-face education group, and the control group.

Data will be collected using the Participant Information Form, HPV Knowledge Scale, and HPV Vaccination Attitude and Intention Form. Measurements will be performed at three time points: before the education (pre-test), immediately after the education (post-test), and one month after the education (follow-up test). The video-based education group will receive the education via a pre-recorded online video, while the face-to-face group will receive the same content in person at the Family Health Center. No education will be provided to the control group; only measurements will be obtained.

Research Questions

Does HPV education delivered through different methods increase HPV knowledge levels among young women?

Does HPV education increase HPV vaccination intention compared with the control group?

Is face-to-face education more effective than video-based education in increasing vaccination intention?

Are the improvements in knowledge and vaccination intention sustained one month after the education?

Read the detailed description

This study is a randomized controlled intervention designed to evaluate the effects of different educational methods on HPV and HPV vaccination knowledge level and vaccination intention among young women aged 18-24 living in the Afşin district of Kahramanmaraş, Türkiye. Participants will be randomly assigned into three groups: control group, video-based education group, and face-to-face education group.

At the beginning of the study, a pre-test will be administered to determine participants' baseline HPV and HPV vaccine knowledge and vaccination intention. Educational interventions prepared in accordance with national health guidelines will be delivered to the intervention groups, while no training will be provided to the control group. Immediately after the education sessions, a post-test will be applied to assess short-term effects, and a follow-up assessment one month later will evaluate the persistence of the effect.

Data will be collected at three time points using an introductory information form, the HPV Knowledge Scale, and the HPV Vaccination Attitude and Intention Form. The findings will be used to compare the effectiveness of different educational methods on HPV knowledge level and vaccination intention.

03

Conditions studied

  • Human Papillomavirus (HPV) Infection
  • HPV Vaccination Acceptance/Intention

Keywords

  • HPV
  • HPV vaccination
  • HPV vaccine acceptance
  • preventive health behavior
  • health education
04

Who can participate

Ages eligible
18 Years to 24 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be included in the study:

Aged 18-24 years,

Residing in Afşin district, Kahramanmaraş province,

Willing to voluntarily participate in the study,

Literate and able to understand survey questions in Turkish,

Have not previously received the HPV vaccine,

Agree to be available throughout the study period (pre-test, post-education test, and 1-month follow-up test),

Young women without physical or cognitive impairments or serious health problems that would prevent participation in the study.

Exclusion criteria

Exclusion Criteria:

Participants will be excluded if they meet any of the following conditions:

Under 18 or over 24 years of age,

Have received the HPV vaccine or started the vaccine series,

Have been diagnosed with HPV infection,

Unable to attend the educational sessions or complete all stages of data collection (pre-test, post-education test, 1-month follow-up test),

Illiterate or unable to understand the study forms in Turkish,

Withdraw from the study or indicate unwillingness to continue participation,

Have serious hearing, vision, or cognitive impairments that would prevent meaningful engagement in the educational sessions.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
159 participants (actual)

Study arms

  • No intervention
    Control Group

    Participants in this group will not receive any HPV education during the study period and will complete the same assessments as the intervention groups at all measurement time points.

  • Experimental
    Video-Based Education Group

    Participants in this group will receive HPV and HPV vaccination education delivered through a standardized educational video prepared in accordance with national health guidelines.

    Behavioral: Video-Based HPV Education

  • Experimental
    Face-to-Face Education Group

    Participants in this group will receive HPV and HPV vaccination education through face-to-face training provided by the researcher using standardized educational materials.

    Behavioral: Face-to-Face HPV Education

Interventions

  • BehavioralVideo-Based HPV Education

    A structured educational video providing information about HPV infection, transmission, prevention, and HPV vaccination.

  • BehavioralFace-to-Face HPV Education

    A structured face-to-face educational session conducted by the researcher covering HPV infection, transmission, prevention, and HPV vaccination.

  • BehavioralVideo-Based HPV Education

    Participants will receive HPV and HPV vaccination education through a standardized educational video including information about HPV transmission, related diseases, prevention methods, and the benefits of vaccination.

  • BehavioralFace-to-Face HPV Education

    Participants will receive HPV and HPV vaccination education through a structured face-to-face session conducted by the researcher using standardized educational materials.

06

What researchers measure

Primary outcomes

  1. HPV Knowledge and Vaccination Intention - Pre-Test

    Young women who consent to participate in the study will complete the Participant Information Form and the HPV Knowledge and Vaccination Intention Scale before receiving any education. This stage aims to determine participants' baseline knowledge and intention to vaccinate.

    Time frame: Before education

Secondary outcomes

  1. HPV Knowledge and Vaccination Intention - Post-Education Test

    Immediately after the intervention, the experimental groups will receive the designated educational methods (video-based education and face-to-face education), and the same scales will be re-administered. This measurement is intended to evaluate the short-term effect of the education. The control group will not receive any education at this stage, only the assessments will be conducted.

    Time frame: Immediately after education

  2. HPV Knowledge and Vaccination Intention - 1-Month Follow-Up Test

    One month after the educational intervention, all groups will complete the same scales again to assess the persistence of changes in knowledge and vaccination intention. This measurement evaluates the sustained effect of the educational interventions.

    Time frame: : 1 month after education

07

Study locations

1 site
  • Afşin Aile Sağlığı Merkezleri
    Kahramanmaraş, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because the dataset contains sensitive personal information related to participants' health, vaccination intention, and demographic details. To protect participant confidentiality and privacy, access to the data is restricted to the research team.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Jan 2026, 1 month.

Of 110 non-industry interventional studies with no phase under Papillomavirus Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's 1 month is below that.

Counting every sponsor, half of 119 studies reached it within 26 months; a quarter within 10 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 19, 2026
StartActual
Dec 15, 2025
Primary completionActual
Jan 15, 2026
CompletionActual
May 14, 2026
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07420556
Lead sponsor
Emel GÜÇLÜ CİHAN
Responsible party
Emel GÜÇLÜ CİHAN (Assistant Professor, Kahramanmaras Sutcu Imam University) — Sponsor-investigator
First posted
Feb 19, 2026
Start date
Dec 15, 2025
Primary completion
Jan 15, 2026
Completion
May 14, 2026
Last update
Aug 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion